- Home
- PMCB vs CERO Comparison
PMCB vs CERO Comparison
Compare PMCB & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- CERO
- Stock Information
- Founded
- PMCB 1996
- CERO 2017
- Country
- PMCB United States
- CERO United States
- Employees
- PMCB N/A
- CERO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- CERO
- Sector
- PMCB Health Care
- CERO
- Exchange
- PMCB Nasdaq
- CERO Nasdaq
- Market Cap
- PMCB 10.5M
- CERO 8.4M
- IPO Year
- PMCB N/A
- CERO N/A
- Fundamental
- Price
- PMCB $1.69
- CERO $2.34
- Analyst Decision
- PMCB
- CERO
- Analyst Count
- PMCB 0
- CERO 0
- Target Price
- PMCB N/A
- CERO N/A
- AVG Volume (30 Days)
- PMCB 15.8K
- CERO 80.5M
- Earning Date
- PMCB 03-17-2025
- CERO 02-20-2025
- Dividend Yield
- PMCB N/A
- CERO N/A
- EPS Growth
- PMCB N/A
- CERO N/A
- EPS
- PMCB 0.74
- CERO N/A
- Revenue
- PMCB N/A
- CERO N/A
- Revenue This Year
- PMCB N/A
- CERO N/A
- Revenue Next Year
- PMCB N/A
- CERO N/A
- P/E Ratio
- PMCB $2.27
- CERO N/A
- Revenue Growth
- PMCB N/A
- CERO N/A
- 52 Week Low
- PMCB $1.39
- CERO $2.22
- 52 Week High
- PMCB $2.58
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- PMCB 56.22
- CERO 32.54
- Support Level
- PMCB $1.50
- CERO $2.83
- Resistance Level
- PMCB $1.80
- CERO $3.50
- Average True Range (ATR)
- PMCB 0.11
- CERO 1.13
- MACD
- PMCB 0.01
- CERO 0.05
- Stochastic Oscillator
- PMCB 61.69
- CERO 1.43
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.